We're doomed we're saved #15

Show notes

In our data-heavy age, data becomes a treasure, a currency, a valuable good. This is true especially for the biotech and pharmaceutical industries, where data can inform the development of novel drugs. But should own biomedical data – and where should the lines between privacy and patient benefit be drawn? In the new episode of We’re doomed, we’re saved, Andreas Horchler and Louise von Stechow discuss new strategies of data sharing and ownership in biomedicine and pharma.

Content and Editing: Louise von Stechow and Andreas Horchler

Disclaimer: Louise von Stechow, Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast.

Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow

Image: Sigmund al4RJ- via Unsplash

References: https://www.biopharminternational.com/view/big-pharma-meets-big-data https://www.forbes.com/sites/forbesbusinesscouncil/2022/05/27/data-is-pharmas-next-blockbuster/ https://www.melloddy.eu/ https://www.pistoiaalliance.org/eventdetails/pistoia-alliances-2023-annual-usa-conference/ https://spectrum.ieee.org/icelands-giant-genome-project-points-to-future-of-medicine https://academic.oup.com/jlb/article/8/2/lsab023/6380070